Blood-Based Biomarkers for Cancer Immunotherapy: Tumor Mutational Burden in Blood (bTMB) is Associated with Improved Atezolizumab (atezo) Efficacy in 2L+ NSCLC (POPLAR and OAK)

A Rittmeyer; D Gandara; M Kowanetz; T Mok; L Fehrenbacher; D Fabrizio; G Otto; C Malboeuf; D Lieber; SM Paul; L Amler; T Riehl; E Schleifman; C Cummings; PS Hegde; W Zou; A Sandler; M Ballinger; DS Shames

doi:10.1055/s-0037-1619250

Pneumologie, Inhaltsverzeichnis

Pneumologie 2018; 72(S 01): S49-S50
DOI: 10.1055/s-0037-1619250

Sektion 11 – Pneumologische Onkologie

Posterbegehung – Titel: Lungenkarzinom II

Georg Thieme Verlag KG Stuttgart · New York

Blood-Based Biomarkers for Cancer Immunotherapy: Tumor Mutational Burden in Blood (bTMB) is Associated with Improved Atezolizumab (atezo) Efficacy in 2L+ NSCLC (POPLAR and OAK)

A Rittmeyer

¹Lungenfachklinik Immenhausen

,

D Gandara

²UC Davis Comprehensive Cancer Center, Sacramento, CA

,

M Kowanetz

³Genentech Inc., South San Francisco

,

T Mok

⁴State Key Laboratory of South China, Hong Kong Cancer Institute, The Chinese University of Hong Kong

,

L Fehrenbacher

⁵Kaiser Permanente Medical Center, Vallejo, USA

,

D Fabrizio

⁶Foundation Medicine Inc., Cambridge, USA

,

G Otto

⁶Foundation Medicine Inc., Cambridge, USA

,

C Malboeuf

⁶Foundation Medicine Inc., Cambridge, USA

,

D Lieber

⁶Foundation Medicine Inc., Cambridge, USA

,

SM Paul

³Genentech Inc., South San Francisco

,

L Amler

³Genentech Inc., South San Francisco

,

T Riehl

³Genentech Inc., South San Francisco

,

E Schleifman

³Genentech Inc., South San Francisco

,

C Cummings

³Genentech Inc., South San Francisco

,

PS Hegde

³Genentech Inc., South San Francisco

,

W Zou

³Genentech Inc., South San Francisco

,

A Sandler

³Genentech Inc., South San Francisco

,

M Ballinger

³Genentech Inc., South San Francisco

,

DS Shames

³Genentech Inc., South San Francisco

› Institutsangaben